Old Web
English
Sign In
Acemap
>
authorDetail
>
Dongmei Zhai
Dongmei Zhai
Boehringer Ingelheim
Dabigatran
Stroke
Medicine
Atrial fibrillation
Concomitant
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study.
2021
European Journal of Internal Medicine
Sake J. Van der Wall
Gregory Y.H. Lip
Christine Teutsch
Oskars Kalējs
Philippe Lyrer
Christian Hall
Sergio Dubner
Hans Christoph Diener
Jonathan L. Halperin
Chang Sheng Ma
Kenneth J. Rothman
Kristina Zint
Dongmei Zhai
Menno V. Huisman
Gloria-Af investigators
Show All
Source
Cite
Save
Citations (0)
Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
2021
Young-Soo Lee
Yong-Seog Oh
Eue-Keun Choi
Alan Koay Choon Chern
Panyapat Jiampo
Aurauma Chutinet
Dicky A. Hanafy
Prabhav Trivedi
Dongmei Zhai
Show All
Source
Cite
Save
Citations (0)
Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran.
2020
Eue-Keun Choi
Young-Soo Lee
Alan Koay Choon Chern
Panyapat Jiampo
Aurauma Chutinet
Dicky A. Hanafy
Prabhav Trivedi
Dongmei Zhai
Yong-Seog Oh
Show All
Source
Cite
Save
Citations (2)
1